Eloxx Pharmaceuticals, Inc. (ELOX) Balance Sheet
ELOX balance sheet, 2025
December 31, 2025 · U.S. dollars$5.3M assets = $17.2M liabilities + −$11.9M equity
Liabilities exceed assets: shareholders’ equity is negative (−$11.9M).
Both columns are drawn to the same scale: what ELOX owns equals what it owes plus shareholders’ equity. Hover a block for its value.
ELOX financial health
Descriptive bands, not a rating. Fiscal 2025.
ELOX balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $9.2M2016 | $5.3M2025 | −6.0%/yr | |
| Total liabilities | $4.7M2016 | $17.2M2025 | +15.6%/yr | |
| Shareholders’ equity | $4.6M2016 | −$11.9M2025 | — | |
| Cash & short-term investments | $810,8082016 | $4.8M2025 | +21.8%/yr | |
| Total debt | $15.8M2019 | $1.0M2025 | −36.8%/yr | |
| Net cash (debt) | $40.6M2019 | $3.8M2025 | −$36.8M | |
| Working capital | $613,6372016 | −$11.9M2025 | −$12.5M | |
| Current ratio | 2.662016 | 0.312025 | −2.36 | |
| Debt / equity | 0.442019 | 0.602021 | +0.17 |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
ELOX assets
ELOX liabilities and equity
ELOX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
ELOX balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $4.8M | $111,000 | $1.1M | $19.5M | $42.6M | $24.7M | $56.3M | $48.7M | $24.2M | $810,808 |
| Cash & equivalents | $4.8M | $111,000 | $1.1M | $19.5M | $42.6M | $24.7M | $22.5M | $48.7M | $24.2M | $810,808 |
| Short-term investments | — | — | — | — | — | — | $33.8M | — | — | — |
| Receivables | $0 | $2.7M | $0 | $0 | $0 | $0 | $26,000 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $479,000 | $147,000 | $414,000 | $661,000 | $913,000 | $1.2M | $1.4M | $1.7M | $355,000 | $171,820 |
| Total current assets | $5.3M | $3.0M | $1.5M | $20.1M | $43.5M | $25.9M | $57.7M | $50.3M | $24.5M | $982,628 |
| Property, plant & equipment (net) | $0 | $0 | $164,000 | $994,000 | $1.7M | $554,000 | $1.1M | $248,000 | $278,000 | $92,554 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $8.1M |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 | $0 | $0 | $30,000 | $113,000 | $129,000 | $0 | $50,770 |
| Total assets | $5.3M | $3.0M | $1.7M | $21.1M | $45.1M | $26.5M | $58.9M | $50.7M | $24.8M | $9.2M |
| Liabilities | ||||||||||
| Accounts payable | $2.7M | $5.3M | $5.7M | $3.0M | $1.4M | $481,000 | $1.9M | $747,000 | $1.5M | — |
| Short-term debt | $1.0M | $6.5M | $2.4M | $4.7M | $657,000 | $5.6M | $4.8M | — | — | — |
| Deferred revenue | — | $13.3M | $13.0M | — | — | — | — | — | — | — |
| Total current liabilities | $17.2M | $27.3M | $22.7M | $23.1M | $10.0M | $9.8M | $11.8M | $7.8M | $3.4M | $368,991 |
| Long-term debt | $0 | $0 | $1.6M | $8.6M | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $0 | $4,000 | $135,000 | $847,000 | — | — | — | — | — | — |
| Other long-term liabilities | $0 | $0 | $2,000 | $135,000 | $12.8M | $6.4M | $10.9M | $0 | $0 | $4.3M |
| Total liabilities | $17.2M | $27.3M | $24.3M | $31.8M | $22.8M | $16.2M | $22.7M | $7.8M | $3.4M | $4.7M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $48,000 | $35,000 | $31,000 | $22,000 | $871,000 | $404,000 | $402,000 | $360,000 | $274,000 | $204,964 |
| Retained earnings (deficit) | −$300.6M | −$294.6M | −$291.4M | −$274.4M | −$238.3M | −$171.6M | −$137.0M | −$86.1M | −$39.0M | −$115.6M |
| Accumulated other comprehensive income | — | — | — | — | — | — | $18,000 | — | — | — |
| Total shareholders' equity | −$11.9M | −$24.3M | −$22.6M | −$10.7M | $22.4M | $10.2M | $36.2M | $42.9M | $21.4M | $4.6M |
| Key figures | ||||||||||
| Total debt | $1.0M | $6.5M | $4.0M | $13.4M | $13.5M | $12.0M | $15.8M | — | — | — |
| Net cash (debt) | $3.8M | −$6.4M | −$2.8M | $6.1M | $29.1M | $12.7M | $40.6M | — | — | — |
| Working capital | −$11.9M | −$24.3M | −$21.1M | −$3.0M | $33.5M | $16.1M | $45.9M | $42.5M | $21.1M | $613,637 |
| Tangible book value | −$11.9M | −$24.3M | −$22.6M | −$10.7M | $22.4M | $10.2M | $36.2M | $42.9M | $21.4M | −$3.5M |
| Book value per share | −$10.61 | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 1.1M | — | — | — | — | — | — | — | — | — |
| Current ratio | 0.31 | 0.11 | 0.07 | 0.87 | 4.37 | 2.63 | 4.89 | 6.45 | 7.16 | 2.66 |
| Quick ratio | 0.28 | 0.10 | 0.05 | 0.84 | 4.28 | 2.51 | 4.77 | 6.23 | 7.06 | 2.20 |
| Debt / equity | — | — | — | — | 0.60 | 1.18 | 0.44 | — | — | — |
| Equity / assets | −225.9% | −817.7% | −1,320.0% | −50.5% | 49.6% | 38.6% | 61.4% | 84.6% | 86.2% | 49.4% |
| Jun '26 | Mar '26 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | Mar '22 | Dec '21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $62.0M | $6.4M | $5.0M | $4.5M | $5.2M | $19.5M | $24.8M | $30.3M | $40.1M | $42.6M |
| Cash & equivalents | $62.0M | $6.4M | $5.0M | $4.5M | $5.2M | $19.5M | $24.8M | $30.3M | $40.1M | $42.6M |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $1.4M | $1.3M | $635,000 | $841,000 | $1.2M | $661,000 | $854,000 | $1.3M | $2.1M | $913,000 |
| Total current assets | $63.4M | $7.7M | $5.6M | $5.4M | $6.4M | $20.1M | $25.7M | $31.6M | $42.1M | $43.5M |
| Property, plant & equipment (net) | $0 | $0 | $413,000 | $611,000 | $797,000 | $994,000 | $1.2M | $1.3M | $1.5M | $1.7M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $849,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total assets | $63.4M | $8.5M | $6.0M | $6.0M | $7.2M | $21.1M | $26.9M | $32.9M | $43.6M | $45.1M |
| Liabilities | ||||||||||
| Accounts payable | $3.0M | $3.0M | $3.1M | $3.1M | $2.4M | $3.0M | $1.6M | $1.9M | $2.9M | $1.4M |
| Short-term debt | — | — | $3.1M | $2.8M | $2.2M | $4.7M | $3.2M | $1.8M | $647,000 | $657,000 |
| Deferred revenue | — | $11.8M | — | — | — | — | — | — | — | — |
| Total current liabilities | $17.0M | $16.1M | $23.5M | $21.3M | $19.5M | $23.1M | $21.7M | $19.5M | $19.2M | $10.0M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $0 | $0 | $2.6M | $3.3M | $4.0M | $8.7M | $10.2M | $11.6M | $12.8M | $12.8M |
| Total liabilities | $17.0M | $16.1M | $26.1M | $24.6M | $23.5M | $31.8M | $31.9M | $31.1M | $31.9M | $22.8M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $40,000 | $51,000 | $31,000 | $25,000 | $22,000 | $22,000 | $871,000 | $871,000 | $871,000 | $871,000 |
| Retained earnings (deficit) | −$308.8M | −$304.3M | −$288.6M | −$285.0M | −$280.6M | −$274.4M | −$268.1M | −$260.6M | −$249.9M | −$238.3M |
| Accumulated other comprehensive income | — | — | — | −$41,000 | — | — | — | — | — | — |
| Total shareholders' equity | $46.4M | −$7.6M | −$20.0M | −$18.6M | −$16.3M | −$10.7M | −$5.0M | $1.8M | $11.7M | $22.4M |
| Key figures | ||||||||||
| Total debt | — | — | $5.8M | $6.1M | $6.2M | $13.4M | $13.4M | $13.4M | $13.4M | $13.5M |
| Net cash (debt) | — | — | −$764,000 | −$1.6M | −$1.1M | $6.1M | $11.4M | $16.9M | $26.7M | $29.1M |
| Working capital | $46.4M | −$8.4M | −$17.8M | −$15.9M | −$13.1M | −$3.0M | $4.0M | $12.1M | $23.0M | $33.5M |
| Tangible book value | $46.4M | −$7.6M | −$20.0M | −$18.6M | −$16.3M | −$10.7M | −$5.0M | $1.8M | $11.7M | $22.4M |
| Book value per share | $6.84 | −$1.73 | — | — | — | — | — | — | — | — |
| Shares outstanding | 6.8M | 4.4M | — | — | — | — | — | — | — | — |
| Current ratio | 3.74 | 0.48 | 0.24 | 0.25 | 0.33 | 0.87 | 1.18 | 1.62 | 2.20 | 4.37 |
| Quick ratio | 3.65 | 0.40 | 0.21 | 0.21 | 0.27 | 0.84 | 1.14 | 1.55 | 2.09 | 4.28 |
| Debt / equity | — | — | — | — | — | — | — | 7.42 | 1.15 | 0.60 |
| Equity / assets | 73.2% | −89.2% | −331.8% | −310.3% | −226.3% | −50.5% | −18.5% | 5.5% | 26.8% | 49.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 17, 2026); data from EODHD.
ELOX financial position
At the end of fiscal 2025 (December 31, 2025), Eloxx Pharmaceuticals had total assets of $5.3 million (up 77.1% from a year earlier), total liabilities of $17.2 million and shareholders' equity of -$11.9 million. It held $4.8 million in cash and short-term investments against $1.0 million of debt, a net cash position of $3.8 million. Its current ratio was 0.31. In the latest quarter (ended June 30, 2026) total assets were $63.4 million and equity $46.4 million.
Related: ELOX income statement, ELOX cash flow statement, ELOX key metrics. See the ELOX stock overview for the latest quote and news.
ELOX balance sheet FAQ
What are Eloxx Pharmaceuticals's total assets?
Eloxx Pharmaceuticals reported total assets of $5.3 million at the end of fiscal 2025 (December 31, 2025), compared with $3.0 million a year earlier.
How much debt does Eloxx Pharmaceuticals have?
Eloxx Pharmaceuticals had $1.0 million of total debt at the end of fiscal 2025, including short-term borrowings. Its debt-to-equity ratio was —.
How much cash does Eloxx Pharmaceuticals have?
Eloxx Pharmaceuticals held $4.8 million in cash and short-term investments at the end of fiscal 2025; with $1.0 million of debt that is net cash of $3.8 million.
What is Eloxx Pharmaceuticals's book value?
Eloxx Pharmaceuticals's shareholders' equity (book value) was -$11.9 million at the end of fiscal 2025, or −$10.61 per share.
What is Eloxx Pharmaceuticals's current ratio?
Eloxx Pharmaceuticals had current assets of $5.3 million and current liabilities of $17.2 million, a current ratio of 0.31 (current liabilities exceed current assets).